{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:58:48Z","timestamp":1767664728437},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10637-022-01312-9","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T10:03:37Z","timestamp":1667556217000},"page":"168-172","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma"],"prefix":"10.1007","volume":"41","author":[{"given":"Fumihiko","family":"Kinoshita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Oku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinkichi","family":"Takamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Fujishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Toyozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensaku","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"1312_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333","journal-title":"CA Cancer J Clin"},{"key":"1312_CR2","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1158\/1078-0432.CCR-11-2370","volume":"18","author":"P Perez-Moreno","year":"2012","unstructured":"Perez-Moreno P, Brambilla E, Thomas R et al (2012) Squamous cell carcinoma of the lung: Molecular subtypes and therapeutic opportunities. Clin Cancer Res 18:2443\u20132451","journal-title":"Clin Cancer Res"},{"key":"1312_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in Untreated EGFR -Mutated Advanced Non\u2013Small-Cell Lung Cancer. N Engl J Med 378:113\u2013125","journal-title":"N Engl J Med"},{"key":"1312_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus crizotinib in untreated ALK-positive non\u2013small-cell lung cancer. N Engl J Med 377:829\u2013838","journal-title":"N Engl J Med"},{"key":"1312_CR5","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Ou S-HI, Bang Y-J et al (2014) Crizotinib in ROS1 -Rearranged Non\u2013Small-Cell Lung Cancer. N Engl J Med 371:1963\u20131971","journal-title":"N Engl J Med"},{"key":"1312_CR6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","volume":"16","author":"N Thatcher","year":"2015","unstructured":"Thatcher N, Hirsch FR, Luft AV et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial. Lancet Oncol 16:763\u2013774","journal-title":"Lancet Oncol"},{"key":"1312_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lungcan.2019.01.005","volume":"129","author":"S Watanabe","year":"2019","unstructured":"Watanabe S, Yoshioka H, Sakai H et al (2019) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan. Lung Cancer 129:55\u201362","journal-title":"Lung Cancer"},{"key":"1312_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, De Vries E et al (2016) RECIST 1.1 - Update and clarification: From the RECIST committee. Eur J Cancer 62:132\u2013137","journal-title":"Eur J Cancer"},{"key":"1312_CR9","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27.US Department of Health and Human Services, National Institutes of Health, National Cancer Institute"},{"key":"1312_CR10","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1111\/1759-7714.13999","volume":"12","author":"A Nakao","year":"2021","unstructured":"Nakao A, Inoue H, Osaki Y et al (2021) Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report. Thorac Cancer 12:2039\u20132042","journal-title":"Thorac Cancer"},{"key":"1312_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198\u2013211","journal-title":"Lancet Oncol"},{"key":"1312_CR12","doi-asserted-by":"publisher","unstructured":"Reck M, Ciuleanu TE, Cobo M et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.ESMO Open.;6. Epub ahead of print 2021. DOI: https:\/\/doi.org\/10.1016\/j.esmoop.2021.100273","DOI":"10.1016\/j.esmoop.2021.100273"},{"key":"1312_CR13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","volume":"15","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares L, Vicente D, Tafreshi A et al (2020) A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol 15:1657\u20131669","journal-title":"J Thorac Oncol"},{"key":"1312_CR14","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus Ipilimumab in Advanced Non\u2013Small-Cell Lung Cancer. N Engl J Med 381:2020\u20132031","journal-title":"N Engl J Med"},{"key":"1312_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","volume":"17","author":"LG Paz-Ares","year":"2022","unstructured":"Paz-Ares LG, Ramalingam SS, Ciuleanu TE et al (2022) First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol 17:289\u2013308","journal-title":"J Thorac Oncol"},{"key":"1312_CR16","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer. N Engl J Med 375:1823\u20131833","journal-title":"N Engl J Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01312-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01312-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01312-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T13:08:00Z","timestamp":1679404080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01312-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01312-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"23 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements and Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}},{"value":"This retrospective research was reviewed and approved by our institutional review board (IRB No. 2019-56).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval:"}},{"value":"Informed consent was obtained from all individual participants included in the study by optout.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate:"}}]}}